Long-Term Safety Study of Inhaled Insulin: An Up to Four-Year Extension of Therapy in Subjects With Type 1 or Type 2 Diabetes Mellitus
Recruiting in Palo Alto (17 mi)
+9 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Pfizer
No Placebo Group
Prior Safety Data
Trial Summary
What is the purpose of this trial?
This is a long-term safety study for Phase 2 subjects who choose to remain on Exubera® (inhaled insulin).
Research Team
PC
Pfizer CT.gov Call Center
Principal Investigator
Pfizer
Eligibility Criteria
Inclusion Criteria
Subjects with Type 1 or Type 2 Diabetes Mellitus who participated in previous Phase 2 extension protocols
Treatment Details
Interventions
- Exubera® (inhaled insulin) (Insulin)
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Exubera® (inhaled insulin)Experimental Treatment1 Intervention
Open label, no comparator
Find a Clinic Near You
Who Is Running the Clinical Trial?
Pfizer
Lead Sponsor
Trials
4,712
Recruited
50,980,000+
Known For
Vaccine Innovations
Top Products
Viagra, Zoloft, Lipitor, Prevnar 13
Albert Bourla
Pfizer
Chief Executive Officer since 2019
PhD in Biotechnology of Reproduction, Aristotle University of Thessaloniki
Patrizia Cavazzoni
Pfizer
Chief Medical Officer
MD from McGill University